Key takeaways about Yutrepia

Yutrepia (treprostinil) is an inhaled medication used to treat two types of pulmonary hypertension: 

  • Pulmonary arterial hypertension, also known as Group 1 PH. 
  • Pulmonary hypertension associated with interstitial lung disease, also known as Group 3 PH. 

Yutrepia works to improve the ability to exercise.  

The Food and Drug Administration approved Yutrepia in May 2025. The FDA approved Tyvaso, the first formulation of inhaled treprostinil, in 2002. The FDA approved Tyvaso DPI, a dry inhalation powder formulation of treprostinil, in 2022.

Each treprostinil formulation or product has its own inhalation device, which can’t be used with the other formulations. The devices aren’t interchangeable.

Treprostinil is a manufactured prostacyclin, a hormone produced by the innermost layer of blood vessels. Prostacyclin helps those blood vessels relax and widen. Many PH patients don’t make enough prostacyclin.

Treprostinil inhalation powder is delivered directly to the lungs to widen narrowed blood vessels. It also can inhibit platelets from clumping together to form blood clots. Relaxing and widening of the blood vessels in the lungs decreases pulmonary pressures. Lower pressure in the pulmonary arteries decreases the resistance or workload of the right ventricle to pump blood to the lungs.

Treprostinil oral inhalation therapy is inhaled through the mouth to deliver the medication directly to the lungs. Treprostinil can be taken as a nebulized solution or by dry powder inhaler. The medication is inhaled three to five times per day with each dose at least four hours apart.

Yutrepia capsules are for oral inhalation only and should be used only with the supplied inhaler. Yutrepia is available in four dose strengths:

  • 26.5 mcg (yellow)
  • 53 mcg (green)
  • 79.5 mcg (blue)
  • 106 mcg (purple)

Depending on your dose, you will need to take one or two capsules. Each capsule is inhaled in two breaths.

About the inhaler

You should use only the capsule-based inhaler to take Yutrepia inhalation powder capsules. The small, pocket-sized inhaler has a base with a mouthpiece, capsule chamber and two blue push buttons.

Discard the inhaler device after seven days of use or 56 actuations, whichever comes first.

Storage

  • Keep capsules in blister packaging to protect them from moisture and light.
  • Remove each capsule only when you’re ready to administer a dose.
  • Store Yutrepia at room temperature.

Treprostinil inhalation powder is a limited-distribution medication, which means you can’t buy it at a local pharmacy. A physician must prescribe the medication, and you’ll need insurance approval before starting therapy. Once you receive prior authorization from your insurance company, a specialty pharmacy nurse will teach you how to administer the medication properly. Specialty pharmacies include Accredo and CVS specialty.

Yutrepia is generally well tolerated. Common side effects include:

  • Cough
  • Headache.
  • Throat irritation and pain.
  • Nausea.
  • Reddening of the face and neck (flushing).
  • Dizziness
  • Fainting or loss of consciousness.
  • Shortness of breath.
  • Diarrhea

Possible serious side effects:

  • Low blood pressure. Your health care team will frequently monitor your blood pressure because of the medication’s potential to lower systemic blood pressure.
  • Risk of bleeding, especially for people who take blood thinners (anticoagulants).
  • Bronchospasm, a tightening of the muscles that line the airways in your lungs.

Monitoring side effects

Talk to your health care team if you experience side effects while using Yutrepia. Your doctor’s office and specialty pharmacy nurse will monitor you for toleration/side effects when you start the medication and when your dosage increases.

Your doctor will assess your ability to exercise will taking treprostinil inhalation powder.

Certain patient populations must take precautions while taking inhaled treprostinil, while others should avoid it. Learn about who can and who shouldn’t take this medication:

Pregnant and breastfeeding patients

Treprostinil inhalation powder hasn’t been studied in pregnant or breastfeeding women. It’s unknown whether the medication will harm an unborn baby or can be passed into breast milk. Talk to your health care provider if you are pregnant, plan to become pregnant or are breastfeeding.

Children and teens

Treprostinil inhalation powder hasn’t been studied in patients younger than 18 years of age.

Tell your health care provider about medications you take (including over-the-counter) before starting a new treatment. Your doctor may need to adjust your medications for systemic blood pressure and heart disease. Possible interactions include:

  • Medicines that decrease blood clotting (anticoagulants).
  • Water pills (diuretics).
  • Gemfibrozil (Lopid) or rifampin (Rimactane, Rifadin, Rifamate, Rifater)

Note: Treprostinil inhalation powder isn’t cleared by dialysis. Treprostinil inhalation powder doesn’t affect warfarin use.

Paying for your medication

Most insurance pays for part of this medication, but some plans have high out-of-pocket costs. Depending on your plan, you might qualify for financial assistance from Liquidia, which makes Yutrepia, through your specialty pharmacy, or a nonprofit organization.

Explore financial assistance

Updated September 2025